- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 4, 2024Trust & Estate Litigation in Minnesota
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Allergan Sales, LLC v. Teva Pharms. USA, Inc.
Upholding recommendation for summary judgment because water was not a “gelling agent” in the context of the patent-in-suit.
October 24, 2017
Case Name: Allergan Sales, LLC v. Teva Pharms. USA, Inc., Civ. No. 2:15-cv-1471-JRG-RSP (Lead), 2017 U.S. Dist. LEXIS 176262 (E.D. Tex. Oct. 24, 2017) (Gilstrap, J.)
Drug Product and Patent(s)-in-Suit: Delzicol® (mesalamine); U.S. Patent No. 6,649,180 (“the ’180 patent”)
Nature of the Case and Issue(s) Presented: The parties submitted claim construction briefing seeking construction of the term “gelling agent.” The magistrate judge construed “gelling agent” as having its plain and ordinary meaning, “a substance that gels the film composition,” then concluded that water could not act as a gelling agent. Based on this construction, the magistrate judge recommended granting Teva’s motion for summary judgment for non-infringement. Allergen objected, but the Article III judge overruled those objections and adopted the magistrate’s conclusions.
Why Teva Prevailed: Teva submitted persuasive expert evidence that water could not function as a gelling agent. Instead, water simply served a passive, not active, role in gelling. Further, there was inventor testimony that water was not a gelling agent. In contrast, Allergen was unable to produce any evidence that water gels the composition of the products at issue in the lawsuit. Accordingly, even with the disputed facts all construed in Allergen’s favor, no reasonable person would find that water serves as a gelling agent. For this reason, the court adopted the magistrate’s recommendation and granted Teva’s motion for summary judgment.
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.